Skip to main content

Table 1 Baseline characteristics of study patients

From: Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma

CharacteristicsCLD patients (n = 142)HCC patients (n = 304)p value
Age (year)a65 (14)72 (14)< 0.001
Sex (male/female)84/58213/910.023
Etiology (HBV/HCV/Others)26/69/4734/156/1140.116
Liver damage (CH/LC)66/7652/252< 0.001
AFP (ng/mL)a3.8 (3.1)15.7 (112.7)< 0.001
DCP (mAU/mL)a20 (9)93 (1140)< 0.001
AST (IU/L)a27 (23)47 (44)< 0.001
ALT (IU/L)a22 (28)35 (32)< 0.001
ALB (g/dL)a4.3 (0.5)3.7 (0.7)< 0.001
T-Bil (mg/dL)a0.9 (0.5)0.9 (0.6)0.612
PLT (× 104/μL)a14.2 (10.2)11.9 (9.7)< 0.001
PT (%)a99 (21)93 (24)0.014
Child-Pugh (A/B/C)125/13/4246/49/90.137
  1. a Data are expressed as median (interquartile range)
  2. Abbreviations, CLD chronic liver disease, HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, CH chronic hepatitis, LC liver cirrhosis, AFP alpha-fetoprotein, DCP des-gamma-carboxy prothrombin, AST aspartate aminotransferase, ALT alanine aminotransferase, ALB albumin, T-Bil total bilirubin, PLT platelet, PT prothrombin time